Neo Comice Pilot; Efficacy of Advanced Semi-automated Functional Magnetic Resonance (MR) Imaging in the Early Prediction of Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy
- To determine the technical feasibility of using MRI in a multicenter setting using the
most commonly available magnetic resonance (MR) systems (i.e., is the trial able to
scan patients to a specific protocol, using different types of MRI machine) measured by
the number of MRI scans not completed to technical specifications (i.e., incorrect
sequences or incomplete scans) or trial protocol (i.e., scans not completed or
completed at the wrong time).
- To determine how reliably the imaging data can be analyzed in a centralized,
semi-automated manner (i.e., can MRI data be reliably transferred from different
centers and analyzed using software based in the center for MR investigations at the
University of Hull) measured by the number of cases where automated data analysis of
completed MRI scans was not possible (i.e., data could not be analyzed at all or data
required manual analysis).
OUTLINE: This is a multicenter study.
Patients undergo magnetic resonance imaging (MRI) scans at baseline, 4-7 days after
beginning after the first course of chemotherapy, at the end of their second course of
chemotherapy, and at the end of their fourth course of chemotherapy (first regimen). MRI
techniques may include dynamic contrast-enhanced, diffusion-weighted, and spectroscopic.
Primary Purpose: Diagnostic
Failed scan rate (i.e., the number of scans that failed protocol) grouped by cause, including patient refusal, protocol violation in timing, major errors in scan protocols, and minor errors in scan protocol
Lindsay W. Turnbull, MD
Hull Royal Infirmary